. 2019 Sep 17;20(18):4590. doi: 10.3390/ijms20184590

Table 1.

Compositions of DC/DC_leu-generating protocols.

DC/DC_leu-Generating Protocols	Composition	Concentration	Sources of DC/DC_leu	Mode of Action	Culture Time	Reference
Picibanil-_PGE1	GM-CSF	500 U/mL	PBMC WB	GM-CSF: induction of myeloid (DC-) differentiation IL-4: induction of DC-differentiation Picibanil (OK-432): lysis product from streptococcus pyogenes; stimulates DC-differentiation PGE₂: increases CCR7-expression and enhances DC-migration PGE₁: effects are comparable to PGE₂	7–10 days
(Pici-_PGE1)	IL-4	250 U/mL
	OK-432	10 µg/mL
	PGE₁	1 µg/mL
Picibanil-_PGE2	GM-CSF	500 U/mL	PBMC WB		7–10 days	[17,20]
(Pici-_PGE2)	IL-4	250 U/mL
	OK-432	10 µg/mL
	PGE₂	1 µg/mL
Kit M^#	GM-CSF	800 U/mL	WB		7–10 days	[47]
	PGE₁	10 µg/mL	WB		7–10 days	[47]
Kit K^#	GM-CSF	800 U/mL	WB		7–10 days	[47]
	PGE₂	1 µg/mL	WB		7–10 days	[47]
Kit I^#	GM-CSF	800 U/mL	WB		7–10 days	[47]
	OK-432	1 µg/mL	WB		7–10 days	[47]

DC dendritic cells; DC_leu dendritic cells of leukemic origin; GM-CSF granulocyte macrophage colony stimulating factor; IL-4 interleukin 4; OK-432 picibanil; PGE₂ prostaglandin E₂; PGE₁ prostaglandin E₁; PBMC peripheral blood mononuclear cells, WB whole blood; ^# 15 801 987.7-1118 European Patent.